NCT00055432终止2 期
Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 试验地点
- 1
研究概览
简要总结
This study hopes to evaluate whether the combination of Gemzar plus Alimta will have any beneficial effects for patients with recurrent platinum-sensitive or platinum-resistant ovarian or peritoneal cancer. Treatments are weekly for two weeks, with the 3rd week off and will be repeated every 21 days. Side effects and the overall safety of the treatment will also be monitored and evaluated. In addition, a Quality of Life questionnaire is part of this study to help measure patient perceived benefits or drawbacks to this treatment regimen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients must have disease that can be measured.
- •Patients must meet criteria for either platinum-resistant or platinum-sensitive ovarian or peritoneal cancer.
- •Patients may only have had one prior platinum-based chemotherapy regimen.
- •Patients must be willing and able to stop all aspirin and NSAID medications immediately before and for a time after each treatment cycle (approx. 5-8 days)
- •Patients must have normal kidney function.
排除标准
- •Patients may not have a Low Malignant Potential or Borderline Ovarian Tumor.
- •Patients may not have received pelvic or abdominal radiotherapy.
- •Patients must not have evidence of or received treatment for another cancer within the last 5 years.
- •Patients must not have been diagnosed with a heart attack in the last 6 months.
- •Patients who are unwilling or unable to take folic acid tablets, vitamin B12 injections or dexamethasone tablets.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving Taxane TherapyBreast NeoplasmsBreast CancerNCT00063570Eli Lilly and Company73
已完成
3 期
A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.Pancreatic NeoplasmsMetastases, NeoplasmNCT00035035Eli Lilly and Company
终止
2 期
Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung CancerNon-Small-Cell Lung CancerNCT00383331Eli Lilly and Company19
已完成
2 期
Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal MesotheliomaMesotheliomaNCT00061477Eli Lilly and Company48
终止
2 期
Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS MutationsMetastatic Colorectal CancerNCT01109615Vejle Hospital40